Immunogenicity and safety of BoostrixTM using a new syringe in 10 to 15-year-old adolescents

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-003768-30

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To demonstrate that Boostrix administered using the new syringe presentation is non-inferior to Boostrix administered using the previous syringe presentation, in terms of immune response to all vaccine antigens, one month after booster vaccination.


Critère d'inclusion

  • Booster immunization of healthy adolescents against diphtheria, tetanus and pertussis

Liens